Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis.

In line with the documented ability of TCZ to induce dyslipidemia, we observed significantly elevated levels of total cholesterol, HDL, and TG, as well as a rise in LDL that did not reach statistical significance in our RA patients following four months of TCZ treatment.

also in 111,027 other papers